IMCR vs. RGEN, PCVX, EXEL, RVMD, HALO, CRSP, KRYS, IBRX, IMVT, and DNLI
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.
Repligen has a net margin of 2.44% compared to Repligen's net margin of -22.60%. Immunocore's return on equity of 3.95% beat Repligen's return on equity.
Repligen has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
97.6% of Repligen shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 9.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Repligen presently has a consensus price target of $197.75, suggesting a potential upside of 35.65%. Immunocore has a consensus price target of $81.85, suggesting a potential upside of 96.37%. Given Repligen's higher probable upside, analysts plainly believe Immunocore is more favorable than Repligen.
Repligen has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Repligen received 348 more outperform votes than Immunocore when rated by MarketBeat users. However, 72.60% of users gave Immunocore an outperform vote while only 68.08% of users gave Repligen an outperform vote.
In the previous week, Immunocore had 4 more articles in the media than Repligen. MarketBeat recorded 8 mentions for Immunocore and 4 mentions for Repligen. Immunocore's average media sentiment score of 1.68 beat Repligen's score of 0.56 indicating that Repligen is being referred to more favorably in the media.
Summary
Repligen beats Immunocore on 13 of the 18 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
